niftify.in

The Economic Times

Panacea, Sanofi settle patent litigation over hexavalent vaccine

Panacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Shan6 vaccine in India and will withdraw its opposition to Panacea's patent. Panacea will forgo claims for damages. The Delhi High Court disposed of the suit on September 13, 2024.

The Economic Times

Panacea Biotec, Sanofi settle patent infringement suit

Panacea Biotec has settled a patent infringement dispute with Sanofi Healthcare India regarding its fully liquid hexavalent vaccine, EasySix. Sanofi agreed not to launch its Shan6 vaccine in India and will withdraw oppositions against Panacea's patent amendment application. The Delhi High Court disposed of the suit on September 13, 2024.

Business Line

Sanofi Consumer Healthcare lists on BSE, NSE

SCHIL’s demerger from Sanofi India, sanctioned by the Mumbai bench of the National Company Law Tribunal, became effective on June 1, 2024

Business Standard

Sanofi to invest $437 million in India global centre, double its workforce

The Hyderabad facility is expected to do a significant amount of documentation work related to drug clinical trials, Roach added

The Economic Times

EU approves Sanofi's Dupixent for 'smoker's lungs'

Sanofi and Regeneron received EU approval for broader use of Dupixent in treating chronic obstructive pulmonary disease (COPD), a significant step achieved faster than in the U.S. The EU Commission approved Dupixent for COPD patients not responsive to standard treatments, marking its expanded use beyond conditions like asthma and eczema.